Pulse Biosciences, Inc. (PLSE)

The first patient was enrolled in the NANOCLAMP AF Study for atrial fibrillation. An earnings call for November 5, 2025, was announced. Inducement grants were announced under Nasdaq Listing Rule 5635(c)(4). Late-breaking data from the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study was presented at a major European conference. Analysts have a consensus "Hold" rating for PLSE, with an average price target of $22.00. The company has reported negative earnings per share (EPS) and a negative return on equity. Insiders have sold more stock than they have bought in the past three months, although insider buying was noted in December 2024.

Specific information regarding demand seasonality for Pulse Biosciences, Inc.'s products and services is not publicly available. While some financial platforms offer tools to analyze stock seasonality, the underlying demand patterns for the company's medical devices are not detailed.

Pulse Biosciences, Inc. is a clinical-stage bioelectric medicine company focused on developing and commercializing medical devices based on its proprietary Tissue NanoPortation (TNP) platform. The company's core technology, Nano-Pulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, aiming to trigger cellular responses without thermal damage. The company operates within the Healthcare sector, specifically in the Medical Instruments & Supplies and Health Care Equipment industries. Its major products include the CellFX® System, CellFX nsPFA Percutaneous Electrode system, CellFX nsPFA Cardiac Clamp, CellFX nsPFA 360° Cardiac Catheter, and The CellFX Consol. Beyond dermatology and aesthetic medicine, Pulse Biosciences is exploring the potential of its NPS platform in oncology, immuno-oncology, wound healing, and bacterial decontamination.

Pulse Biosciences, Inc. is headquartered in Miami, Florida, and also maintains an office in Hayward, California. The company operates in North America and Europe, collaborating with key opinion leaders in dermatology and medical research institutions.

Information specifically detailing Pulse Biosciences, Inc.'s brand reputation was not readily available. The news primarily focuses on product development, clinical trials, and financial reporting, which are generally positive indicators for a bioelectric medicine company.

Pulse Biosciences, Inc. has a mixed ownership structure, with a significant portion held by insiders. Robert W. Duggan is the largest individual shareholder, owning approximately 73.42% of the company's shares. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, Bank Of America Corp /de/, Geode Capital Management, Llc, State Street Corp, Griffin Asset Management Inc., and Northern Trust Corp. Approximately 8.90% of the stock is held by institutional shareholders.